anticoagulants

News

Cadrenal Therapeutics acquires eXIthera’s Factor XIa inhibitors

Cadrenal will acquire eXIthera’s intravenous Factor XIa inhibitor frunexian, oral inhibitor EP-7327, and additional novel FXIa small molecules.

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

Sections

Sections

Sections

Sections

Sections

Sections

Cadrenal Therapeutics acquires eXIthera’s Factor XIa inhibitors

Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry

Leading Artificial Intelligence (AI) Companies in Pharma

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief